REG - Avacta Group PLC - AVA3996 data poster presented at AACR

AvactaAnnouncement

17/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230417:nRSQ3420Wa&default-theme=true

RNS Number : 3420W  Avacta Group PLC  17 April 2023

 

 

17 April 2023

 

Avacta Group plc

 

("Avacta" or the "Company" and, together with its subsidiary undertakings, the
"Group")

 

Avacta Presents AVA3996 Pre-clinical Data at the American Association for
Cancer Research Meeting

 

Poster and explanatory video now available on the Company's website

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, announces that it has
presented pre-clinical data describing the novel pre|CISION(TM) proteasome
inhibitor, AVA3996, at the 2023 American Association for Cancer Research
(AACR) Annual Meeting in Florida, USA, one of the largest international cancer
research meetings.

 

Proteasome inhibitors are effective anti-cancer drugs that we believe could
benefit from application of our preICISION(TM) technology to markedly expand
their use. While the global proteasome inhibitors market is expected to
reach nearly $2.3 billion by 2026 1 , these drugs are primarily indicated for
the treatment of multiple myeloma. Severe, dose limiting toxicities have
prevented application to a broader range of cancers, in particular to solid
tumours.

 

AVA3996 is the second of Avacta's pre|CISION(TM) chemotherapies. AVA3996
combines a proprietary proteasome inhibitor (called AVA2727D) with Avacta's
pre|CISION(TM) tumour targeting chemistry, creating the potential to reduce
the systemic toxicities and thereby make it possible to treat solid tumours
with a proteasome inhibitor for the first time. AVA3996 is in pre-clinical
development with the aim of submitting an Investigational New Drug (IND)
application to allow clinical development to begin during 2024.

 

Pre-clinical data generated to date and presented at AACR show that:

·      The release of the active proteasome inhibitor (AVA2727D) from
AVA3996 is specific to the enzyme FAP, which is upregulated in most solid
tumours. This underpins the potential to target the proteasome inhibitor to
tumour tissue.

·      In a head to head study, AVA2727D kills cancers cells (ex-vivo)
as effectively as bortezomib (Takeda's Velcade) which is one of the approved
proteasome inhibitors on the market.

·      In three different in-vivo (mouse) cancer models (melanoma,
sarcoma and colorectal cancer), AVA3996 was as effective as bortezomib in
restricting tumour growth, and in the case of the melanoma model, as effective
as trametinib, the standard of care for unresectable melanoma.

·      The significant toxicities associated with bortezomib observed in
these in-vivo models were not observed in the case of AVA3996, suggesting that
the systemic exposure to the drug had been reduced due to the tumour targeting
of the pre|CISION(TM) chemistry in AVA3996.

 

The AVA3996 poster presentation, along with an explanatory video reviewing the
pre-clinical data are available on the Company's web site via the links below.
The video also reviews the published AVA6000 phase 1a clinical data to date.
AVA6000 is the Company's lead pre|CISION(TM) programme that is currently in
the later stages of a phase 1a dose escalation safety study.

 

AVA3996 pre-clinical data poster: https://avacta.com/about/resources/
(https://avacta.com/about/resources/)

Video: https://avacta.com/investors/documents-presentations/
(https://avacta.com/investors/documents-presentations/)

 

Dr Alastair Smith, Chief Executive Officer, Avacta Group plc, commented:

 

"We are delighted with the progress being made in the pre-clinical development
of AVA3996, the second drug candidate based on our preICISION(TM) platform.
The potential to apply a proteasome inhibitor to the treatment of solid
tumours is very exciting and, as can be seen from our poster presented at the
prestigious AACR meeting, the pre-clinical data we are generating is very
encouraging in that regard.

 

We are focused on accelerating AVA3996 through to IND filing as soon as
possible so that it can follow AVA6000 into the clinic next year."

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                                Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                         www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)                               Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares   www.stifel.com (http://www.stifel.com/)
 / William Palmer-Brown

 FTI Consulting (Financial Media and IR)                                         Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw / George Kendrick                                      Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                                  Tel: +44 (0)7891 477 378

 Lily Jeffery                                                                    lily.jeffery@zymecommunications.com

                                                                               (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com)

 

Avacta Group plc is a life sciences company working to improve people's health
and well-being through innovative oncology drugs and powerful diagnostics.
Operating through two divisions, Diagnostics and Therapeutics, the Group's
mission is to provide professionals and consumers with solutions that improve
healthcare, fitness and well-being.

 

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is
building a wholly owned pipeline of novel Affimer(®) immunotherapies and
pre|CISION™ tumour targeted chemotherapies. This approach is designed to
address the lack of a durable response to current cancer immunotherapies
experienced by most patients and reduce the severe systemic toxicities caused
by chemotherapies. There are five programmes in the pipeline as well as
several global research collaborations and licensing partnerships. Avacta's
lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the
established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in
patients with locally advanced or metastatic selected solid tumours.

 

The Affimer(®) platform is an alternative to antibodies that has been
designed to address many of the drawbacks of antibodies which, despite their
shortcomings, currently dominate the immuno-diagnostics and
immuno-therapeutics markets.

 

The pre|CISION™ tumour targeting platform can be used to modify a
chemotherapy in order to selectively release the active drug in tumour tissue
thereby reducing the systemic exposure that causes damage to healthy tissues.
pre|CISION™ modified chemotherapies are designed to reduce the side effects
and improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro
diagnostic (IVD) solutions. The Division is growing rapidly through an M&A
strategy to deliver a global scale IVD business providing market leading
solutions for healthcare professionals and consumers to inform treatment and
monitor health and well-being. In October 2022, Avacta acquired Launch
Diagnostics which serves the hospital pathology laboratory market in the UK
and Europe. Avacta Diagnostic's research and development centre in Wetherby,
UK uses its proprietary Affimer(®) platform to differentiate immunodiagnostic
products to provide marketing leading performance.

 

To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

 

 

 1  https://www.expertmarketresearch.com/reports/proteasome-inhibitors-market
(https://www.expertmarketresearch.com/reports/proteasome-inhibitors-market)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFFFWMEDSEFL